Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Breast Cancer

  Free Subscription


Articles published in Anticancer Res

Retrieve available abstracts of 226 articles:
HTML format
Text format



Single Articles


    May 2018
  1. CHANG J, Charalel R, Noda C, Ramaswamy R, et al
    Liver-dominant Breast Cancer Metastasis: A Comparative Outcomes Study of Chemoembolization Versus Radioembolization.
    Anticancer Res. 2018;38:3063-3068.
    PubMed     Text format     Abstract available


  2. LUMACHI F, Basso SMM, Camozzi V, Spaziante R, et al
    Bone Mineral Density as a Potential Predictive Factor for Luminal-type Breast Cancer in Postmenopausal Women.
    Anticancer Res. 2018;38:3049-3054.
    PubMed     Text format     Abstract available


  3. GOTO W, Kashiwagi S, Asano Y, Takada K, et al
    Eribulin Promotes Antitumor Immune Responses in Patients with Locally Advanced or Metastatic Breast Cancer.
    Anticancer Res. 2018;38:2929-2938.
    PubMed     Text format     Abstract available


  4. KORONOWICZ AA, Drozdowska M, Banks P, Piasna-Slupecka E, et al
    Fatty Acids of CLA-enriched Egg Yolks Can Induce Mitochondrial Pathway of Apoptosis in MCF-7 Breast Cancer Cells.
    Anticancer Res. 2018;38:2861-2870.
    PubMed     Text format     Abstract available


  5. MINAFRA L, Bravata V, Cammarata FP, Russo G, et al
    Radiation Gene-expression Signatures in Primary Breast Cancer Cells.
    Anticancer Res. 2018;38:2707-2715.
    PubMed     Text format     Abstract available


  6. REINHARDT A, Liu H, Ma Y, Zhou Y, et al
    Tumor Cell-selective Synergism of TRAIL- and ATRA-induced Cytotoxicity in Breast Cancer Cells.
    Anticancer Res. 2018;38:2669-2682.
    PubMed     Text format     Abstract available


  7. TUNGSUKRUTHAI S, Petpiroon N, Chanvorachote P
    Molecular Mechanisms of Breast Cancer Metastasis and Potential Anti-metastatic Compounds.
    Anticancer Res. 2018;38:2607-2618.
    PubMed     Text format     Abstract available


  8. LEHMANN-CHE J, Miquel C, Wong J, Callens C, et al
    First French Pilot Quality Assessment of the EndoPredict Test for Early Luminal Breast Carcinoma.
    Anticancer Res. 2018;38:2909-2914.
    PubMed     Text format     Abstract available


  9. LIU LC, Wu YC, Kuo SC, Ho CT, et al
    2-Phenylnaphthyridin-4-one Derivative LYF-11 Inhibits Interleukin-6-mediated Epithelial-to-Mesenchymal Transition via the Inhibition of JAK2/STAT3 Signaling Pathway in MCF-7 Cells.
    Anticancer Res. 2018;38:2849-2859.
    PubMed     Text format     Abstract available


  10. TATARA T, Mukohara T, Tanaka R, Shimono Y, et al
    3D Culture Represents Apoptosis Induced by Trastuzumab Better than 2D Monolayer Culture.
    Anticancer Res. 2018;38:2831-2839.
    PubMed     Text format     Abstract available


  11. OKARVI SM, Aljammaz I
    Preparation and In Vitro and In Vivo Characterization of the Tumor-specific Antigen-derived Peptide as a Potential Candidate for Targeting Human Epidermal Growth Factor Receptor 2-positive Breast Carcinomas.
    Anticancer Res. 2018;38:2823-2830.
    PubMed     Text format     Abstract available


    April 2018
  12. INOUE Y, Yamashita N, Ueo H, Tanaka K, et al
    The Clinical Usefulness of the LigaSure Small Jaw in Axillary Lymph Node Dissection in Patients with Breast Cancer.
    Anticancer Res. 2018;38:2359-2362.
    PubMed     Text format     Abstract available


  13. ASANO Y, Kashiwagi S, Goto W, Takada K, et al
    Prediction of Treatment Response to Neoadjuvant Chemotherapy in Breast Cancer by Subtype Using Tumor-infiltrating Lymphocytes.
    Anticancer Res. 2018;38:2311-2321.
    PubMed     Text format     Abstract available


  14. TAKADA K, Kashiwagi S, Goto W, Asano Y, et al
    Analysis of HER Family (HER1-4) Expression as a Biomarker in Combination Therapy with Pertuzumab, Trastuzumab and Docetaxel for Advanced HER2-positive Breast Cancer.
    Anticancer Res. 2018;38:2285-2294.
    PubMed     Text format     Abstract available


  15. TUOHINEN SS, Keski-Pukkila K, Skytta T, Huhtala H, et al
    Radiotherapy-induced Early ECG Changes and Their Comparison with Echocardiography in Patients with Early-stage Breast Cancer.
    Anticancer Res. 2018;38:2207-2215.
    PubMed     Text format     Abstract available


  16. HSIAO CL, Liu LC, Shih TC, Chuang CL, et al
    The Association of Matrix Metalloproteinase-8 Promoter Genotypes in Breast Cancer.
    Anticancer Res. 2018;38:2181-2185.
    PubMed     Text format     Abstract available


  17. ORSARIA P, Caredda E, Genova F, Materazzo M, et al
    Additional Nodal Disease Prediction in Breast Cancer with Sentinel Lymph Node Metastasis Based on Clinicopathological Features.
    Anticancer Res. 2018;38:2109-2117.
    PubMed     Text format     Abstract available


  18. UEMATSU N, Zhao Y, Kiyomi A, Yuan BO, et al
    Chemo-sensitivity of Two-dimensional Monolayer and Three-dimensional Spheroid of Breast Cancer MCF-7 Cells to Daunorubicin, Docetaxel, and Arsenic Disulfide.
    Anticancer Res. 2018;38:2101-2108.
    PubMed     Text format     Abstract available


  19. JUZENIENE A, Bernoulli J, Suominen M, Halleen J, et al
    Antitumor Activity of Novel Bone-seeking, alpha-emitting (224)Ra-solution in a Breast Cancer Skeletal Metastases Model.
    Anticancer Res. 2018;38:1947-1955.
    PubMed     Text format     Abstract available


  20. PARK HL, Kim KY, Park JS, Shin JE, et al
    Clinicopathological Analysis of Ultrasound-guided Vacuum-assisted Breast Biopsy for the Diagnosis and Treatment of Breast Disease.
    Anticancer Res. 2018;38:2455-2462.
    PubMed     Text format     Abstract available


  21. YU JK, Yue CH, Pan YR, Chiu YW, et al
    Isochlorogenic Acid C Reverses Epithelial-Mesenchymal Transition via Down-regulation of EGFR Pathway in MDA-MB-231 cells.
    Anticancer Res. 2018;38:2127-2135.
    PubMed     Text format     Abstract available


  22. LITWIN M, Szczepanska-Buda A, Michalowska D, Grzegrzolka J, et al
    Aberrant Expression of PIWIL1 and PIWIL2 and Their Clinical Significance in Ductal Breast Carcinoma.
    Anticancer Res. 2018;38:2021-2030.
    PubMed     Text format     Abstract available


  23. NIEMIEC J, Adamczyk A, Harazin-Lechowska A, Ambicka A, et al
    Podoplanin-positive Cancer-associated Stromal Fibroblasts in Primary Tumor and Synchronous Lymph Node Metastases of HER2-overexpressing Breast Carcinomas.
    Anticancer Res. 2018;38:1957-1965.
    PubMed     Text format     Abstract available


    March 2018
  24. GOMES I, Miranda A, Nunes C
    Spatiotemporal Analysis of Breast Cancer Incidence: A Study in Southern Portugal Between 2005 and 2012.
    Anticancer Res. 2018;38:1797-1805.
    PubMed     Text format     Abstract available


  25. ALEXOPOULOU E, Katsila T, Tolia M, Tsoukalas N, et al
    An Exploratory Study of Radiation Dermatitis in Breast Cancer Patients.
    Anticancer Res. 2018;38:1615-1622.
    PubMed     Text format     Abstract available


  26. FRITZ P, Dippon J, Muller S, Goletz S, et al
    Is Mistletoe Treatment Beneficial in Invasive Breast Cancer? A New Approach to an Unresolved Problem.
    Anticancer Res. 2018;38:1585-1593.
    PubMed     Text format     Abstract available


  27. KOI Y, Koga C, Akiyoshi S, Masuda T, et al
    Impact of Visceral Metastasis on Efficacy of Fulvestrant in Patients with Hormone Receptor-positive Recurrent Breast Cancer.
    Anticancer Res. 2018;38:1579-1584.
    PubMed     Text format     Abstract available


  28. DIMAS DT, Perlepe CD, Sergentanis TN, Misitzis I, et al
    The Prognostic Significance of Hsp70/Hsp90 Expression in Breast Cancer: A Systematic Review and Meta-analysis.
    Anticancer Res. 2018;38:1551-1562.
    PubMed     Text format     Abstract available


  29. DE CREMOUX P, Hamy AS, Lehmann-Che J, Scott V, et al
    COX2/PTGS2 Expression Is Predictive of Response to Neoadjuvant Celecoxib in HER2-negative Breast Cancer Patients.
    Anticancer Res. 2018;38:1485-1490.
    PubMed     Text format     Abstract available


  30. HA GH, Kim DY, Breuer EK, Kim CK, et al
    Combination Treatment of Polo-Like Kinase 1 and Tankyrase-1 Inhibitors Enhances Anticancer Effect in Triple-negative Breast Cancer Cells.
    Anticancer Res. 2018;38:1303-1310.
    PubMed     Text format     Abstract available


  31. UJHELYI M, Pukancsik D, Kelemen P, Kovacs E, et al
    Barriers to Organized Mammography Screening Programs in Hungary: A Questionnaire-based Study of 3,313 Women.
    Anticancer Res. 2018;38:1727-1734.
    PubMed     Text format     Abstract available


  32. EL HAGE CHEHADE H, Mokbel K
    Is Adjuvant Endocrine Therapy Indicated for DCIS Patients After Complete Surgical Excision?
    Anticancer Res. 2018;38:1263-1266.
    PubMed     Text format     Abstract available


    February 2018
  33. FRIEDRICH M, Reichert K, Woeste A, Polack S, et al
    Effects of Combined Treatment with Vitamin D and COX2 Inhibitors on Breast Cancer Cell Lines.
    Anticancer Res. 2018;38:1201-1207.
    PubMed     Text format     Abstract available


  34. FUJII T, Horiguchi J, Yanagita Y, Koibuchi Y, et al
    Phase II Study of S-1 plus Trastuzumab for HER2-positive Metastatic Breast Cancer (GBCCSG-01).
    Anticancer Res. 2018;38:905-909.
    PubMed     Text format     Abstract available


  35. NAWA-NISHIGAKI M, Kobayashi R, Suzuki A, Hirose C, et al
    Control of Nausea and Vomiting in Patients Receiving Anthracycline/Cyclophosphamide Chemotherapy for Breast Cancer.
    Anticancer Res. 2018;38:877-884.
    PubMed     Text format     Abstract available


  36. GERA R, Mokbel R, Igor I, Mokbel K, et al
    Does the Use of Hair Dyes Increase the Risk of Developing Breast Cancer? A Meta-analysis and Review of the Literature.
    Anticancer Res. 2018;38:707-716.
    PubMed     Text format     Abstract available


  37. BELKACEMI L, Atkins JL, Yang LU, Gadgil P, et al
    Phosphaplatin Anti-tumor Effect Enhanced by Liposomes Partly via an Up-regulation of PEDF in Breast Cancer.
    Anticancer Res. 2018;38:623-646.
    PubMed     Text format     Abstract available


  38. LUCZYNSKA E, Niemiec J, Heinze S, Adamczyk A, et al
    Intensity and Pattern of Enhancement on CESM: Prognostic Significance and its Relation to Expression of Podoplanin in Tumor Stroma - A Preliminary Report.
    Anticancer Res. 2018;38:1085-1095.
    PubMed     Text format     Abstract available


  39. NIEDER C, Kampe TA, Engljahringer K
    Does Patient-reported Dyspnea Reflect Thoracic Disease Characteristics in Patients with Incurable Cancer?
    Anticancer Res. 2018;38:901-904.
    PubMed     Text format     Abstract available


    January 2018
  40. SVOBODOVA S, Kucera R, Fiala O, Marie K, et al
    CEA, CA 15-3, and TPS as Prognostic Factors in the Follow-up Monitoring of Patients After Radical Surgery for Breast Cancer.
    Anticancer Res. 2018;38:465-469.
    PubMed     Text format     Abstract available


  41. KASHIWAGI S, Asano Y, Goto W, Takada K, et al
    Mesenchymal-epithelial Transition and Tumor Vascular Remodeling in Eribulin Chemotherapy for Breast Cancer.
    Anticancer Res. 2018;38:401-410.
    PubMed     Text format     Abstract available


  42. TAKASHIMA T, Kawajiri H, Nishimori T, Tei S, et al
    Safety and Efficacy of Low-dose Nanoparticle Albumin-bound Paclitaxel for HER2-negative Metastatic Breast Cancer.
    Anticancer Res. 2018;38:379-383.
    PubMed     Text format     Abstract available


  43. CHAMARAUX-TRAN TN, Mathelin C, Aprahamian M, Joshi GP, et al
    Antitumor Effects of Lidocaine on Human Breast Cancer Cells: An In Vitro and In Vivo Experimental Trial.
    Anticancer Res. 2018;38:95-105.
    PubMed     Text format     Abstract available


  44. JARDEL P, Vignot S, Cutuli B, Creisson A, et al
    Should Adjuvant Radiation Therapy Be Systematically Proposed for Male Breast Cancer? A Systematic Review.
    Anticancer Res. 2018;38:23-31.
    PubMed     Text format     Abstract available


    December 2017
  45. PESSINA F, Navarria P, Cozzi L, Franceschini D, et al
    Outcome Evaluation of HER2 Breast Cancer Patients with Limited Brain Metastasis.
    Anticancer Res. 2017;37:7057-7062.
    PubMed     Text format     Abstract available


  46. YAMANOUCHI K, Kuba S, Sakimura C, Morita M, et al
    The Relationship Between Peripheral Neuropathy Induced by Docetaxel and Systemic Inflammation-based Parameters in Patients with Breast Cancer.
    Anticancer Res. 2017;37:6947-6951.
    PubMed     Text format     Abstract available


  47. MOKBEL K, Wazir U, El Hage Chehade H, Manson A, et al
    A Comparison of the Performance of EndoPredict Clinical and NHS PREDICT in 120 Patients Treated for ER-positive Breast Cancer.
    Anticancer Res. 2017;37:6863-6869.
    PubMed     Text format     Abstract available


  48. NIMEUS E, Folkesson E, Nodin B, Hartman L, et al
    Androgen Receptor in Stage I-II Primary Breast Cancer -Prognostic Value and Distribution in Subgroups.
    Anticancer Res. 2017;37:6845-6853.
    PubMed     Text format     Abstract available


  49. AULA H, Skytta T, Tuohinen S, Luukkaala T, et al
    Adjuvant Breast Cancer Treatments Induce Changes in Homoarginine Level - A Prospective Observational Study.
    Anticancer Res. 2017;37:6815-6824.
    PubMed     Text format     Abstract available


  50. PEREIRA MC, Mohammed R, VAN Otterlo WAL, DE Koning CB, et al
    Evaluation of the Effects of Aminonaphthoquinone Derivatives in Combination with Curcumin Against ER-positive Breast Cancer and Related Tumours.
    Anticancer Res. 2017;37:6749-6759.
    PubMed     Text format     Abstract available


  51. STOPE MB, Weiss M, Koensgen D, Popp SL, et al
    Y-box Binding Protein-1 Enhances Oncogenic Transforming Growth Factor beta Signaling in Breast Cancer Cells via Triggering Phospho-Activation of Smad2.
    Anticancer Res. 2017;37:6745-6748.
    PubMed     Text format     Abstract available


  52. MATSUI C, Takatani-Nakase T, Maeda S, Nakase I, et al
    Potential Roles of GLUT12 for Glucose Sensing and Cellular Migration in MCF-7 Human Breast Cancer Cells Under High Glucose Conditions.
    Anticancer Res. 2017;37:6715-6722.
    PubMed     Text format     Abstract available


  53. KAR A, Liu B, Gutierrez-Hartmann A
    ESE-1 Knockdown Attenuates Growth in Trastuzumab-resistant HER2(+) Breast Cancer Cells.
    Anticancer Res. 2017;37:6583-6591.
    PubMed     Text format     Abstract available


  54. SPARTALIS E, Tsilimigras DI, Charalampoudis P, Karachaliou GS, et al
    The "Yin and Yang" of Platelet-rich Plasma in Breast Reconstruction After Mastectomy or Lumpectomy for Breast Cancer.
    Anticancer Res. 2017;37:6557-6562.
    PubMed     Text format     Abstract available


  55. MIRKA H, Tupy R, Narsanska A, Hes O, et al
    Pre-surgical Multiparametric Assessment of Breast Lesions Using 3-Tesla Magnetic Resonance.
    Anticancer Res. 2017;37:6965-6970.
    PubMed     Text format     Abstract available


  56. SAPINHO G, Alho I, Bicho M, Coelho C, et al
    Total Knockdown of LMW-PTP in MDA-MB-231 Cells Reduces Osteoclastogenesis.
    Anticancer Res. 2017;37:6671-6677.
    PubMed     Text format     Abstract available


  57. MANOUCHEHRI JM, Kalafatis M
    Sensitization of rhTRAIL-resistant Triple-negative Breast Carcinoma Through Silibinin Co-Treatment.
    Anticancer Res. 2017;37:6593-6599.
    PubMed     Text format     Abstract available


  58. CHRISTOPOULOS PF, Vlachogiannis NI, Vogkou CT, Koutsilieris M, et al
    The Role of the Androgen Receptor Signaling in Breast Malignancies.
    Anticancer Res. 2017;37:6533-6540.
    PubMed     Text format     Abstract available


    November 2017
  59. MATSUI A, Tatibana A, Suzuki N, Hirata M, et al
    Evaluation of Efficacy and Safety of Upfront Weekly Nanoparticle Albumin-bound Paclitaxel for HER2-negative Breast Cancer.
    Anticancer Res. 2017;37:6481-6488.
    PubMed     Text format     Abstract available


  60. SHEIKH IA, Jiffri EH, Kamal MA, Ashraf GM, et al
    Lactoperoxidase, an Antimicrobial Milk Protein, as a Potential Activator of Carcinogenic Heterocyclic Amines in Breast Cancer.
    Anticancer Res. 2017;37:6415-6420.
    PubMed     Text format     Abstract available


  61. SHEIKH IA, Beg MA, Yasir M
    Molecular Interactions of Carcinogenic Aromatic Amines, 4-Aminobiphenyl and 4,4'-Diaminobiphenyl, with Lactoperoxidase - Insight to Breast Cancer.
    Anticancer Res. 2017;37:6245-6249.
    PubMed     Text format     Abstract available


  62. JEON D, Kim H, Nam K, Oh S, et al
    Cytotoxic Effect of Nano-SiO2 in Human Breast Cancer Cells via Modulation of EGFR Signaling Cascades.
    Anticancer Res. 2017;37:6189-6197.
    PubMed     Text format     Abstract available


  63. WAKIMOTO R, Ono M, Takeshima M, Higuchi T, et al
    Differential Anticancer Activity of Pterostilbene Against Three Subtypes of Human Breast Cancer Cells.
    Anticancer Res. 2017;37:6153-6159.
    PubMed     Text format     Abstract available


  64. DU J, Sun Y, Lu YY, Lau E, et al
    Berberine and Evodiamine Act Synergistically Against Human Breast Cancer MCF-7 Cells by Inducing Cell Cycle Arrest and Apoptosis.
    Anticancer Res. 2017;37:6141-6151.
    PubMed     Text format     Abstract available


    October 2017
  65. SHOJI F, Yamashita N, Inoue Y, Kozuma Y, et al
    Surgical Resection and Outcome of Synchronous and Metachronous Primary Lung Cancer in Breast Cancer Patients.
    Anticancer Res. 2017;37:5871-5876.
    PubMed     Text format     Abstract available


  66. KARMAKAR MK, Samy W, Lee A, Li JW, et al
    Survival Analysis of Patients with Breast Cancer Undergoing a Modified Radical Mastectomy With or Without a Thoracic Paravertebral Block: a 5-Year Follow-up of a Randomized Controlled Trial.
    Anticancer Res. 2017;37:5813-5820.
    PubMed     Text format     Abstract available


  67. HE K, Wang X, Guan X, Yu Q, et al
    Vinorelbine Plus Gemcitabine or Cisplatin as First-line Treatment of HER2-negative Advanced Breast Cancer.
    Anticancer Res. 2017;37:5647-5653.
    PubMed     Text format     Abstract available


  68. KASHIWAGI S, Asano Y, Goto W, Takada K, et al
    Using TILs to Predict Therapeutic Effect of Chemotherapy (Pertuzumab, Trastuzumab, Docetaxel) on HER2-positive Breast Cancer.
    Anticancer Res. 2017;37:5623-5630.
    PubMed     Text format     Abstract available


  69. CHU QD, Zhou M, Medeiros KL, Peddi P, et al
    Impact of CALGB 9343 Trial and Sociodemographic Variation on Patterns of Adjuvant Radiation Therapy Practice for Elderly Women (>/=70 Years) with Stage I, Estrogen Receptor-positive Breast Cancer: Analysis of the National Cancer Data Base.
    Anticancer Res. 2017;37:5585-5594.
    PubMed     Text format     Abstract available


  70. PHAM DH, Kim JS, Kim SK, Shin DJ, et al
    Effects of ADAM10 and ADAM17 Inhibitors on Natural Killer Cell Expansion and Antibody-dependent Cellular Cytotoxicity Against Breast Cancer Cells In Vitro.
    Anticancer Res. 2017;37:5507-5513.
    PubMed     Text format     Abstract available


  71. BOBIN-DUBIGEON C, Chauvin A, Brillaud-Meflah V, Boiffard F, et al
    Liver X Receptor (LXR)-regulated Genes of Cholesterol Trafficking and Breast Cancer Severity.
    Anticancer Res. 2017;37:5495-5498.
    PubMed     Text format     Abstract available


  72. CALIS IU, Cosan DT, Mutlu F
    Effects of S1P1 and S1P3 in ER+ and ER- Breast Cancer Cells.
    Anticancer Res. 2017;37:5469-5475.
    PubMed     Text format     Abstract available


  73. GIGLI S, Amabile MI, DI Pastena F, DE Luca A, et al
    Lipofilling Outcomes Mimicking Breast Cancer Recurrence: Case Report and Update of the Literature.
    Anticancer Res. 2017;37:5395-5398.
    PubMed     Text format     Abstract available


  74. HARUNA F, Lipsett A, Marignol L
    Topical Management of Acute Radiation Dermatitis in Breast Cancer Patients: A Systematic Review and Meta-Analysis.
    Anticancer Res. 2017;37:5343-5353.
    PubMed     Text format     Abstract available


  75. GLASSMAN D, Hignett S, Rehman S, Linforth R, et al
    Adjuvant Endocrine Therapy for Hormone-positive Breast Cancer, Focusing on Ovarian Suppression and Extended Treatment: An Update.
    Anticancer Res. 2017;37:5329-5341.
    PubMed     Text format     Abstract available


  76. GRZEGRZOLKA J, Wojtyra P, Biala M, Piotrowska A, et al
    Correlation Between Expression of Twist and Podoplanin in Ductal Breast Carcinoma.
    Anticancer Res. 2017;37:5485-5493.
    PubMed     Text format     Abstract available


    September 2017
  77. KRAMMER J, Stepniewski K, Kaiser CG, Brade J, et al
    Value of Additional Digital Breast Tomosynthesis for Preoperative Staging of Breast Cancer in Dense Breasts.
    Anticancer Res. 2017;37:5255-5261.
    PubMed     Text format     Abstract available


  78. YAMASHITA N, Tokunaga E, Yamamoto H, Shimizu C, et al
    The Local Recurrence of Breast Cancer with Squamous Metaplasia and Obvious Histological Heterogeneity.
    Anticancer Res. 2017;37:5249-5254.
    PubMed     Text format     Abstract available


  79. RICCIARDI E, Tomao F, Aletti G, Bazzurini L, et al
    Risk-reducing Salpingo-Oophorectomy in Women at Higher Risk of Ovarian and Breast Cancer: A Single Institution Prospective Series.
    Anticancer Res. 2017;37:5241-5248.
    PubMed     Text format     Abstract available


  80. WAKAHARA M, Sakabe T, Kubouchi Y, Hosoya K, et al
    Subcellular Localization of Maspin Correlates with Histone Deacetylase 1 Expression in Human Breast Cancer.
    Anticancer Res. 2017;37:5071-5077.
    PubMed     Text format     Abstract available


  81. PAN E, Tung L, Ragab O, Morocco E, et al
    Inflammatory Breast Cancer Outcomes in a Contemporary Series.
    Anticancer Res. 2017;37:5057-5063.
    PubMed     Text format     Abstract available


  82. CHOU AK, Hsiao CL, Shih TC, Wang HC, et al
    The Contribution of Matrix Metalloproteinase-7 Promoter Genotypes in Breast Cancer in Taiwan.
    Anticancer Res. 2017;37:4973-4977.
    PubMed     Text format     Abstract available


  83. KORASHY HM, Maayah ZH, Al Anazi FE, Alsaad AM, et al
    Sunitinib Inhibits Breast Cancer Cell Proliferation by Inducing Apoptosis, Cell-cycle Arrest and DNA Repair While Inhibiting NF-kappaB Signaling Pathways.
    Anticancer Res. 2017;37:4899-4909.
    PubMed     Text format     Abstract available


  84. TIMMER M, Werner JM, Rohn G, Ortmann M, et al
    Discordance and Conversion Rates of Progesterone-, Estrogen-, and HER2/neu-Receptor Status in Primary Breast Cancer and Brain Metastasis Mainly Triggered by Hormone Therapy.
    Anticancer Res. 2017;37:4859-4865.
    PubMed     Text format     Abstract available


  85. FANG QI, Wang X, Luo G, Yu M, et al
    Increased CXCL8 Expression Is Negatively Correlated with the Overall Survival of Patients with ER-Negative Breast Cancer.
    Anticancer Res. 2017;37:4845-4852.
    PubMed     Text format     Abstract available


  86. KIM D, Radin D, Leonardi D
    Probing the Molecular Mechanisms Governing the Oncolytic Activity of Paeonia suffruticosa on Triple-negative Breast Cancer Cells In Vitro.
    Anticancer Res. 2017;37:4813-4819.
    PubMed     Text format     Abstract available


  87. KUBAN-JANKOWSKA A, Sahu KK, Gorska-Ponikowska M, Tuszynski JA, et al
    Inhibitory Activity of Iron Chelators ATA and DFO on MCF-7 Breast Cancer Cells and Phosphatases PTP1B and SHP2.
    Anticancer Res. 2017;37:4799-4806.
    PubMed     Text format     Abstract available


  88. ISHITOBI M, Fukui R, Hashimoto Y, Kittaka N, et al
    Safety for Repeat Lumpectomy Without Radiotherapy for Ipsilateral Breast Tumor Recurrence.
    Anticancer Res. 2017;37:5293-5299.
    PubMed     Text format     Abstract available


  89. EICHLER C, Abrar S, Puppe J, Arndt M, et al
    Detection of Ductal Carcinoma In Situ by Ultrasound and Mammography: Size-dependent Inaccuracy.
    Anticancer Res. 2017;37:5065-5070.
    PubMed     Text format     Abstract available


  90. FUJII T, Yanai K, Tokuda S, Nakazawa Y, et al
    Clinicopathological Features of Ductal Carcinoma In Situ from 18F-FDG-PET Findings.
    Anticancer Res. 2017;37:5053-5056.
    PubMed     Text format     Abstract available


  91. UEHARA S, Saito K, Asami H, Ohta Y, et al
    Role of ARHGAP24 in ADP Ribosylation Factor 6 (ARF6)-dependent Pseudopod Formation in Human Breast Carcinoma Cells.
    Anticancer Res. 2017;37:4837-4844.
    PubMed     Text format     Abstract available


    August 2017
  92. ZHOU B, Xu L, Ye J, Xin L, et al
    The Prognostic Value of the 8th Edition of the American Joint Committee on Cancer (AJCC) Staging System in HER2-Enriched Subtype Breast Cancer, a Retrospective Analysis.
    Anticancer Res. 2017;37:4615-4621.
    PubMed     Text format     Abstract available


  93. LANG Z, Wu Y, Li C, Li X, et al
    Multifocal and Multicentric Breast Carcinoma: A Significantly More Aggressive Tumor than Unifocal Breast Cancer.
    Anticancer Res. 2017;37:4593-4598.
    PubMed     Text format     Abstract available


  94. QIN T, Zeng YD, Lu Q, Zhang X, et al
    Nomogram Model of LNR Predicts Survival in Premenopausal Patients with Node-positive Luminal Breast Cancer.
    Anticancer Res. 2017;37:4575-4586.
    PubMed     Text format     Abstract available


  95. YE J, Wang W, Xin L, Owen S, et al
    The Clinicopathological Factors Associated with Disease Progression in Luminal A Breast Cancer and Characteristics of Metastasis: A Retrospective Study from A Single Center in China.
    Anticancer Res. 2017;37:4549-4556.
    PubMed     Text format     Abstract available


  96. ZENG Y, Li Q, Qin T, Li S, et al
    Impact of a 21-Gene Recurrence Score Test on the Choice of Adjuvant Chemotherapy for Hormone Receptor-positive Early-stage Breast Cancer: A Prospective Study.
    Anticancer Res. 2017;37:4539-4547.
    PubMed     Text format     Abstract available


  97. MALIK MFA, Riaz SK, Waqar SH, Haq F, et al
    Role of Plexin B1 in a Breast Cancer Cohort of Pakistani Patients and its Contribution Towards Cancer Metastasis as Indicated by an In Vitro Model.
    Anticancer Res. 2017;37:4483-4488.
    PubMed     Text format     Abstract available


  98. LI Z, Peng Z, Gu S, Zheng J, et al
    Global Analysis of miRNA-mRNA Interaction Network in Breast Cancer with Brain Metastasis.
    Anticancer Res. 2017;37:4455-4468.
    PubMed     Text format     Abstract available


  99. RIAZ SK, Ye L, Sahar NE, Aman D, et al
    Transcriptional Profiling of Sonic Hedgehog in a Prospective Cohort of Breast Cancer in a Pakistani Population.
    Anticancer Res. 2017;37:4449-4454.
    PubMed     Text format     Abstract available


  100. WANG L, Qi Y, Xiong Y, Peng Z, et al
    Ezrin-Radixin-Moesin Binding Phosphoprotein 50 (EBP50) Suppresses the Metastasis of Breast Cancer and HeLa Cells by Inhibiting Matrix Metalloproteinase-2 Activity.
    Anticancer Res. 2017;37:4353-4360.
    PubMed     Text format     Abstract available


  101. LIANG G, Liu Z, Tan L, Su AN, et al
    HIF1alpha-associated circDENND4C Promotes Proliferation of Breast Cancer Cells in Hypoxic Environment.
    Anticancer Res. 2017;37:4337-4343.
    PubMed     Text format     Abstract available


  102. LIU Z, Liang G, Tan L, Su AN, et al
    High-efficient Screening Method for Identification of Key Genes in Breast Cancer Through Microarray and Bioinformatics.
    Anticancer Res. 2017;37:4329-4335.
    PubMed     Text format     Abstract available


  103. UHERCIK M, Sanders AJ, Owen S, Davies EL, et al
    Clinical Significance of PD1 and PDL1 in Human Breast Cancer.
    Anticancer Res. 2017;37:4249-4254.
    PubMed     Text format     Abstract available


  104. KLAPKO O, Ghoulam E, Jakate S, Eswaran S, et al
    Anastrozole-induced Autoimmune Hepatitis: A Rare Complication of Breast Cancer Therapy.
    Anticancer Res. 2017;37:4173-4176.
    PubMed     Text format     Abstract available


  105. CARBONNELLE D, Luu TH, Chaillou C, Huvelin JM, et al
    LXR Activation Down-regulates Lipid Raft Markers FLOT2 and DHHC5 in MCF-7 Breast Cancer Cells.
    Anticancer Res. 2017;37:4067-4073.
    PubMed     Text format     Abstract available


  106. SOBKOWICZ AD, Sanders AJ, Mason MD, Jiang WG, et al
    Potential Implication of Paxillin in Cancer Establishment Within the Bone Environment.
    Anticancer Res. 2017;37:4255-4268.
    PubMed     Text format     Abstract available


    July 2017
  107. REMO M, Abraham I, Kankanala V, Chacra W, et al
    Hepatitis B Reactivation in a Patient Receiving Chemotherapy for Breast Cancer: A Case Report.
    Anticancer Res. 2017;37:3791-3793.
    PubMed     Text format     Abstract available


  108. MESCHER C, Ding C, Defor T, Konety S, et al
    Left Ventricular Ejection Fraction Screening and Clinical Decision-making in Metastatic HER2-positive Breast Cancer.
    Anticancer Res. 2017;37:3751-3755.
    PubMed     Text format     Abstract available


  109. CHIRICO A, D'Aiuto G, Penon A, Mallia L, et al
    Self-Efficacy for Coping with Cancer Enhances the Effect of Reiki Treatments During the Pre-Surgery Phase of Breast Cancer Patients.
    Anticancer Res. 2017;37:3657-3665.
    PubMed     Text format     Abstract available


  110. ORFANIDOU T, Xanthopoulos K, Dafou D, Pseftogas A, et al
    Down-regulation of the Tumor Suppressor CYLD Enhances the Transformed Phenotype of Human Breast Cancer Cells.
    Anticancer Res. 2017;37:3493-3503.
    PubMed     Text format     Abstract available


  111. ALCANTARA DZ, Soliman IJS, Pobre RF, Naguib RNG, et al
    Effects of Pulsed Electromagnetic Fields on Breast Cancer Cell Line MCF 7 Using Absorption Spectroscopy.
    Anticancer Res. 2017;37:3453-3459.
    PubMed     Text format     Abstract available


  112. HU T, Su F, Jiang W, Dart DA, et al
    Overexpression of Activin Receptor-like Kinase 7 in Breast Cancer Cells Is Associated with Decreased Cell Growth and Adhesion.
    Anticancer Res. 2017;37:3441-3451.
    PubMed     Text format     Abstract available


  113. KOBAYASHI H, Hamasaki M, Morishita T, Inoue T, et al
    Analysis of Evolving Clinicopathological Features of Metastatic Brain Tumors Over 30 Years of Surgical Management.
    Anticancer Res. 2017;37:3969-3974.
    PubMed     Text format     Abstract available


  114. KONDO H, Shimono Y, Mukohyama J, Tanaka Y, et al
    Discordance of MCM7 mRNA and its Intronic MicroRNA Levels Under Hypoxia.
    Anticancer Res. 2017;37:3885-3890.
    PubMed     Text format     Abstract available


  115. MADEKIVI V, Bostrom P, Aaltonen R, Vahlberg T, et al
    The Sentinel Node with Isolated Breast Tumor Cells or Micrometastases. Benefits and Risks of Axillary Dissection.
    Anticancer Res. 2017;37:3757-3762.
    PubMed     Text format     Abstract available


  116. MARIAMPILLAI AI, Cruz JPD, Suh J, Sivapiragasam A, et al
    Cancer Antigen 72-4 for the Monitoring of Advanced Tumors of the Gastrointestinal Tract, Lung, Breast and Ovaries.
    Anticancer Res. 2017;37:3649-3656.
    PubMed     Text format     Abstract available


    June 2017
  117. FURRER D, Jacob S, Caron C, Sanschagrin F, et al
    Concordance of HER2 Immunohistochemistry and Fluorescence In Situ Hybridization Using Tissue Microarray in Breast Cancer.
    Anticancer Res. 2017;37:3323-3329.
    PubMed     Text format     Abstract available


  118. STAMPFLI SF, Akhmedov A, Hausladen S, Varga Z, et al
    Tissue Factor Expression Does Not Predict Mortality in Breast Cancer Patients.
    Anticancer Res. 2017;37:3259-3264.
    PubMed     Text format     Abstract available


  119. BANYS-PALUCHOWSKI M, Witzel I, Riethdorf S, Rack B, et al
    Clinical Relevance of Serum HER2 and Circulating Tumor Cell Detection in Metastatic Breast Cancer Patients.
    Anticancer Res. 2017;37:3117-3128.
    PubMed     Text format     Abstract available


  120. GAVRESSEA T, Kalogeras KT, Koliou GA, Zagouri F, et al
    The Prognostic Value of the Immunohistochemical Expression of Phosphorylated RB and p16 Proteins in Association with Cyclin D1 and the p53 Pathway in a Large Cohort of Patients with Breast Cancer Treated with Taxane-based Adjuvant Chemotherapy.
    Anticancer Res. 2017;37:2947-2957.
    PubMed     Text format     Abstract available


  121. CHRISTOPOULOS PF, Papageorgiou E, Petraki C, Koutsilieris M, et al
    The COOH-terminus of the IGF-1Ec Isoform Enhances the Proliferation and Migration of Human MCF-7 Breast Cancer Cells.
    Anticancer Res. 2017;37:2899-2912.
    PubMed     Text format     Abstract available


  122. KUBAN-JANKOWSKA A, Gorska-Ponikowska M, Wozniak M
    Lipoic Acid Decreases the Viability of Breast Cancer Cells and Activity of PTP1B and SHP2.
    Anticancer Res. 2017;37:2893-2898.
    PubMed     Text format     Abstract available


  123. NEUHAUSEN SL, Shani H, Boker LK, Steele L, et al
    Primary Peritoneal Serous Carcinoma in Men: A Rare and Non-BRCA-associated Entity.
    Anticancer Res. 2017;37:3069-3072.
    PubMed     Text format     Abstract available


    May 2017
  124. BYSTRICKY B, Cierna Z, Sieberova G, Janega P, et al
    Relationship Between Circulating Tumor Cells and Annexin A2 in Early Breast Cancer Patients.
    Anticancer Res. 2017;37:2727-2734.
    PubMed     Text format     Abstract available


  125. ESKELINEN M, Selander T, Ollonen P, Korhonen R, et al
    Moderate/severe Depression (MADRS) Can Affect the Quality of Life and Outcome Among Patients Admitted to Breast Cancer Diagnosis Unit.
    Anticancer Res. 2017;37:2641-2647.
    PubMed     Text format     Abstract available


  126. ANGELINI S, Botticelli A, Onesti CE, Giusti R, et al
    Pharmacogenetic Approach to Toxicity in Breast Cancer Patients Treated with Taxanes.
    Anticancer Res. 2017;37:2633-2639.
    PubMed     Text format     Abstract available


  127. MIYATA M, Ohguri T, Yahara K, Yamaguchi S, et al
    Salvage Radiotherapy for Solitary Metachronous Bone Metastasis in Patients with Breast Cancer.
    Anticancer Res. 2017;37:2575-2579.
    PubMed     Text format     Abstract available


  128. KHAN GN, Kim EJ, Shin TS, Lee SH, et al
    Azacytidine-induced Chemosensitivity to Doxorubicin in Human Breast Cancer MCF7 Cells.
    Anticancer Res. 2017;37:2355-2364.
    PubMed     Text format     Abstract available


  129. STRATI TM, Kotoula V, Kostopoulos I, Manousou K, et al
    Prognostic Subcellular Notch2, Notch3 and Jagged1 Localization Patterns in Early Triple-negative Breast Cancer.
    Anticancer Res. 2017;37:2323-2334.
    PubMed     Text format     Abstract available


  130. JIANG XP, Elliott RL
    Decreased Iron in Cancer Cells and Their Microenvironment Improves Cytolysis of Breast Cancer Cells by Natural Killer Cells.
    Anticancer Res. 2017;37:2297-2305.
    PubMed     Text format     Abstract available


  131. DA CRUZ PAULA A, Lopes C
    Implications of Different Cancer Stem Cell Phenotypes in Breast Cancer.
    Anticancer Res. 2017;37:2173-2183.
    PubMed     Text format     Abstract available


    April 2017
  132. THANGARAJAH F, Enninga I, Malter W, Hamacher S, et al
    A Retrospective Analysis of Ki-67 Index and its Prognostic Significance in Over 800 Primary Breast Cancer Cases.
    Anticancer Res. 2017;37:1957-1964.
    PubMed     Text format     Abstract available


  133. INOUE Y, Yamashita N, Tokunaga E, Tanaka K, et al
    A Locally Advanced Breast Cancer that Achieved pCR with Pertuzumab, Trastuzumab and Docetaxel: Case Report.
    Anticancer Res. 2017;37:1917-1921.
    PubMed     Text format     Abstract available


  134. OKU Y, Nishiya N, Tsuda K, Shibazaki M, et al
    Dynamic Phenotypic Transition of Breast Cancer Cells In Vitro Revealed by Self-floating Cell Culture.
    Anticancer Res. 2017;37:1793-1797.
    PubMed     Text format     Abstract available


  135. BYSTRICKY B, Jurisova S, Karaba M, Minarik G, et al
    Relationship Between Circulating Tumor Cells and Tissue Plasminogen Activator in Patients with Early Breast Cancer.
    Anticancer Res. 2017;37:1787-1791.
    PubMed     Text format     Abstract available


  136. KIM KY, Park KI, Kim SH, Yu SN, et al
    Salinomycin Induces Reactive Oxygen Species and Apoptosis in Aggressive Breast Cancer Cells as Mediated with Regulation of Autophagy.
    Anticancer Res. 2017;37:1747-1758.
    PubMed     Text format     Abstract available


  137. DAS T, Nair RR, Green R, Padhee S, et al
    Actinomycin D Down-regulates SOX2 Expression and Induces Death in Breast Cancer Stem Cells.
    Anticancer Res. 2017;37:1655-1663.
    PubMed     Text format     Abstract available


  138. ACUNA UM, Curley RW Jr, Fatima N, Ahmed S, et al
    Differential Effect of Wortmannolone Derivatives on MDA-MB-231 Breast Cancer Cells.
    Anticancer Res. 2017;37:1617-1623.
    PubMed     Text format     Abstract available


  139. JELINEK M, Kabelova A, Sramek J, Seitz J, et al
    Differing Mechanisms of Death Induction by Fluorinated Taxane SB-T-12854 in Breast Cancer Cells.
    Anticancer Res. 2017;37:1581-1590.
    PubMed     Text format     Abstract available


  140. CHIRICO A, Serpentini S, Merluzzi T, Mallia L, et al
    Self-efficacy for Coping Moderates the Effects of Distress on Quality of Life in Palliative Cancer Care.
    Anticancer Res. 2017;37:1609-1615.
    PubMed     Text format     Abstract available


  141. KAISER CG, Herold M, Krammer J, Baltzer P, et al
    Prognostic Value of "Prepectoral Edema" in MR-mammography.
    Anticancer Res. 2017;37:1989-1995.
    PubMed     Text format     Abstract available


  142. VOGL UM, Ohler L, Rasic M, Frischer JM, et al
    Evaluation of Prognostic Immune Signatures in Patients with Breast, Colorectal and Pancreatic Cancer Receiving Chemotherapy.
    Anticancer Res. 2017;37:1947-1955.
    PubMed     Text format     Abstract available


    March 2017
  143. KIM HA, Kim JH, Choi HS, Kim YG, et al
    Core Needle Biopsy Specimens Are More Appropriate than Surgical Specimens for Evaluating the Expression of Phosphoproteins as Biological Markers in Invasive Breast Cancer.
    Anticancer Res. 2017;37:1409-1412.
    PubMed     Text format     Abstract available


  144. DIERAS V, Pop S, Berger F, Dujaric ME, et al
    First-line Bevacizumab and Paclitaxel for HER2-negative Metastatic Breast Cancer: A French Retrospective Observational Study.
    Anticancer Res. 2017;37:1403-1407.
    PubMed     Text format     Abstract available


  145. WENDT C, Lindblom A, Arver B, VON Wachenfeldt A, et al
    Parent of Origin and Prognosis in Familial Breast Cancer in Sweden.
    Anticancer Res. 2017;37:1257-1262.
    PubMed     Text format     Abstract available


  146. MACK N, Mazzio EA, Bauer D, Flores-Rozas H, et al
    Stable shRNA Silencing of Lactate Dehydrogenase A (LDHA) in Human MDA-MB-231 Breast Cancer Cells Fails to Alter Lactic Acid Production, Glycolytic Activity, ATP or Survival.
    Anticancer Res. 2017;37:1205-1212.
    PubMed     Text format     Abstract available


  147. WINDRICHOVA J, Fuchsova R, Kucera R, Topolcan O, et al
    MIC1/GDF15 as a Bone Metastatic Disease Biomarker.
    Anticancer Res. 2017;37:1501-1505.
    PubMed     Text format     Abstract available


  148. SEKIDO Y, Ohigashi S, Takahashi T, Hayashi N, et al
    Familial Gastrointestinal Stromal Tumor with Germline KIT Mutations Accompanying Hereditary Breast and Ovarian Cancer Syndrome.
    Anticancer Res. 2017;37:1425-1431.
    PubMed     Text format     Abstract available


  149. IIZUKA D, Sasatani M, Barcellos-Hoff MH, Kamiya K, et al
    Hydrogen Peroxide Enhances TGFbeta-mediated Epithelial-to-Mesenchymal Transition in Human Mammary Epithelial MCF-10A Cells.
    Anticancer Res. 2017;37:987-995.
    PubMed     Text format     Abstract available


    February 2017
  150. ILENKO A, Sergent F, Mercuzot A, Zitoun M, et al
    Could Patients Older than 75 Years Benefit from a Systematic Breast Cancer Screening Program?
    Anticancer Res. 2017;37:903-907.
    PubMed     Text format     Abstract available


  151. LAWLER G, Leech M
    Dose Sparing Potential of Deep Inspiration Breath-hold Technique for Left Breast Cancer Radiotherapy Organs-at-risk.
    Anticancer Res. 2017;37:883-890.
    PubMed     Text format     Abstract available


  152. ESKELINEN M, Korhonen R, Selander T, Ollonen P, et al
    Beck Depression Inventory as a Predictor of Long-term Outcome Among Patients Admitted to the Breast Cancer Diagnosis Unit: A 25-year Cohort Study in Finland.
    Anticancer Res. 2017;37:819-824.
    PubMed     Text format     Abstract available


  153. WU HC, Southey MC, Hibshoosh H, Santella RM, et al
    DNA Methylation in Breast Tumor from High-risk Women in the Breast Cancer Family Registry.
    Anticancer Res. 2017;37:659-664.
    PubMed     Text format     Abstract available


  154. ONISHI H, Suyama K, Yamasaki A, Oyama Y, et al
    CD24 Modulates Chemosensitivity of MCF-7 Breast Cancer Cells.
    Anticancer Res. 2017;37:561-565.
    PubMed     Text format     Abstract available


    January 2017

  155. Radiation Therapy Techniques and Treatment Planning for Breast Cancer.
    Anticancer Res. 2017;37:369-370.
    PubMed     Text format    



  156. The Pathobiology of Breast Cancer.
    Anticancer Res. 2017;37:365.
    PubMed     Text format    


  157. YANG X, DU G, Yu Z, Si Y, et al
    A Novel NHERF1 Mutation in Human Breast Cancer and Effects on Malignant Progression.
    Anticancer Res. 2017;37:67-73.
    PubMed     Text format     Abstract available


  158. YANO S, Takehara K, Kishimoto H, Tazawa H, et al
    Comparison of Tumor Recurrence After Resection of Highly- and Poorly-Metastatic Triple-negative Breast Cancer in Orthotopic Nude-Mouse Models.
    Anticancer Res. 2017;37:57-60.
    PubMed     Text format     Abstract available


  159. DAMASKOS C, Valsami S, Kontos M, Spartalis E, et al
    Histone Deacetylase Inhibitors: An Attractive Therapeutic Strategy Against Breast Cancer.
    Anticancer Res. 2017;37:35-46.
    PubMed     Text format     Abstract available


  160. STRIEN L, Joensuu K, Heikkila P, Leidenius MH, et al
    Different Expression Patterns of CXCR4, CCR7, Maspin and FOXP3 in Luminal Breast Cancers and Their Sentinel Node Metastases.
    Anticancer Res. 2017;37:175-182.
    PubMed     Text format     Abstract available


  161. GIPPONI M, Baldelli I, Atzori G, Fregatti P, et al
    Tumescent Anesthesia in Skin- and Nipple-sparing Mastectomy: Results of a Prospective Clinical Study.
    Anticancer Res. 2017;37:349-352.
    PubMed     Text format     Abstract available


  162. SCHRODER L, Koch J, Mahner S, Kost BP, et al
    The Effects of Petroselinum Crispum on Estrogen Receptor-positive Benign and Malignant Mammary Cells (MCF12A/MCF7).
    Anticancer Res. 2017;37:95-102.
    PubMed     Text format     Abstract available


    December 2016
  163. RAY A, Khong B, Khong HT
    A Case Report of Pneumocystis Jiroveci Pneumonia in a Patient with Metastatic Breast Cancer.
    Anticancer Res. 2016;36:6673-6676.
    PubMed     Text format     Abstract available


  164. LUKESOVA L, Vrana D, Svach I, Zlamalova N, et al
    Prognostic Influence of Internal Mammary Node Drainage in Patients with Early-stage Breast Cancer.
    Anticancer Res. 2016;36:6641-6646.
    PubMed     Text format     Abstract available


  165. SAKAGUCHI K, Nakatsukasa K, Taguchi T
    Phase I Study of Triweekly Nab-Paclitaxel Combined with S-1 in Patients with HER2-negative Metastatic Breast Cancer.
    Anticancer Res. 2016;36:6515-6519.
    PubMed     Text format     Abstract available


  166. TANAKA S, Iwamoto M, Kimura K, Takahashi Y, et al
    A Phase II Study of Adjuvant Chemotherapy of Tegafur-Uracil for Patients with Breast Cancer with HER2-negative Pathologic Residual Invasive Disease After Neoadjuvant Chemotherapy.
    Anticancer Res. 2016;36:6505-6509.
    PubMed     Text format     Abstract available


  167. TIAINEN L, Tanner M, Lahdenpera O, Vihinen P, et al
    Bevacizumab Combined with Docetaxel or Paclitaxel as First-line Treatment of HER2-negative Metastatic Breast Cancer.
    Anticancer Res. 2016;36:6431-6438.
    PubMed     Text format     Abstract available


  168. RAMDANI LH, Talhi O, Taibi N, Delort L, et al
    Effects of Spiro-bisheterocycles on Proliferation and Apoptosis in Human Breast Cancer Cell Lines.
    Anticancer Res. 2016;36:6399-6408.
    PubMed     Text format     Abstract available


  169. LEE J, Jung JH, Chae YS, Park HY, et al
    Long Noncoding RNA snaR Regulates Proliferation, Migration and Invasion of Triple-negative Breast Cancer Cells.
    Anticancer Res. 2016;36:6289-6295.
    PubMed     Text format     Abstract available


  170. YANO S, Takehara K, Kishimoto H, Tazawa H, et al
    In Vivo Selection of Intermediately- and Highly-Malignant Variants of Triple-negative Breast Cancer in Orthotopic Nude Mouse Models.
    Anticancer Res. 2016;36:6273-6277.
    PubMed     Text format     Abstract available


    November 2016
  171. SHINDEN Y, Kijima Y, Hirata M, Arima H, et al
    Clinical Significance of the Histoculture Drug Response Assay in Breast Cancer.
    Anticancer Res. 2016;36:6173-6178.
    PubMed     Text format     Abstract available


  172. LEE SJ, Park BN, Roh JH, An YS, et al
    Enhancing the Therapeutic Efficacy of 2-Deoxyglucose in Breast Cancer Cells Using Cell-cycle Synchronization.
    Anticancer Res. 2016;36:5975-5980.
    PubMed     Text format     Abstract available


  173. PIRES BR, DE Amorim IS, Souza LD, Rodrigues JA, et al
    Targeting Cellular Signaling Pathways in Breast Cancer Stem Cells and its Implication for Cancer Treatment.
    Anticancer Res. 2016;36:5681-5691.
    PubMed     Text format     Abstract available


  174. VOUTSADAKIS IA
    Immune Blockade Inhibition in Breast Cancer.
    Anticancer Res. 2016;36:5607-5622.
    PubMed     Text format     Abstract available


    October 2016
  175. WALDREP AR, Avery EJ, Rose FF Jr, Midathada MV, et al
    Breast Cancer Subtype Influences the Accuracy of Predicting Pathologic Response by Imaging and Clinical Breast Exam After Neoadjuvant Chemotherapy.
    Anticancer Res. 2016;36:5389-5395.
    PubMed     Text format     Abstract available


  176. QIN W, Holick MF, Sorensen W, Walker CR, et al
    Vitamin D3 Treatment Influences PGE2 and TGFbeta in Normal and Increased Breast Cancer Risk Women.
    Anticancer Res. 2016;36:5347-5353.
    PubMed     Text format     Abstract available


  177. VILSMAIER T, Rack B, Konig A, Friese K, et al
    Influence of Circulating Tumour Cells on Production of IL-1alpha, IL-1beta and IL-12 in Sera of Patients with Primary Diagnosis of Breast Cancer Before Treatment.
    Anticancer Res. 2016;36:5227-5236.
    PubMed     Text format     Abstract available


  178. TAKEDA S, Okazaki H, Kudo T, Kakizoe K, et al
    Bongkrekic Acid as a Warburg Effect Modulator in Long-term Estradiol-deprived MCF-7 Breast Cancer Cells.
    Anticancer Res. 2016;36:5171-5182.
    PubMed     Text format     Abstract available


  179. GANGAPURAM M, Jean R, Mazzio E, Badisa R, et al
    Substituted Tetrahydroisoquinolines as Microtubule-destabilizing Agents in Triple Negative Human Breast Cancer Cells.
    Anticancer Res. 2016;36:5043-5052.
    PubMed     Text format     Abstract available


  180. SHAVERDIAN N, Wang J, Levin-Epstein R, Schaue D, et al
    Pro-inflammatory State Portends Poor Outcomes with Stereotactic Radiosurgery for Brain Metastases.
    Anticancer Res. 2016;36:5333-5337.
    PubMed     Text format     Abstract available


  181. STAHL JM, Hong JC, Lester-Coll NH, Kann BH, et al
    Chest Wall Deformity in the Radiation Oncology Clinic.
    Anticancer Res. 2016;36:5295-5300.
    PubMed     Text format     Abstract available


  182. FUJII T, Yajima R, Kurozumi S, Higuchi T, et al
    Clinical Significance of 18F-FDG-PET in Invasive Lobular Carcinoma.
    Anticancer Res. 2016;36:5481-5485.
    PubMed     Text format     Abstract available


    September 2016
  183. RIOS N, Adaskina N, Fromke C, Papendorf F, et al
    The Benefit of Baseline Staging-Risk Assessment of Distant Breast Cancer Metastases by Tumor Stage.
    Anticancer Res. 2016;36:4909-14.
    PubMed     Text format     Abstract available


  184. KIM YJ, Kim K, Lee R, Kim J, et al
    Two-year Follow-up of Volumetric-modulated Arc Therapy for Treating Internal Mammary Nodes in Locally Advanced Breast Cancer.
    Anticancer Res. 2016;36:4847-51.
    PubMed     Text format     Abstract available


  185. HEPP P, Andergassen U, Jager B, Trapp E, et al
    Association of CA27.29 and Circulating Tumor Cells Before and at Different Times After Adjuvant Chemotherapy in Patients with Early-stage Breast Cancer - The SUCCESS Trial.
    Anticancer Res. 2016;36:4771-6.
    PubMed     Text format     Abstract available


  186. FURRER D, Jacob S, Caron C, Sanschagrin F, et al
    Tissue Microarray Is a Reliable Tool for the Evaluation of HER2 Amplification in Breast Cancer.
    Anticancer Res. 2016;36:4661-6.
    PubMed     Text format     Abstract available


  187. WAZIR U, El Hage Chehade H, Headon H, Oteifa M, et al
    Oncological Safety of Lipofilling in Patients with Breast Cancer: A Meta-analysis and Update on Clinical Practice.
    Anticancer Res. 2016;36:4521-8.
    PubMed     Text format     Abstract available


  188. KAPPIL M, Terry MB, Delgado-Cruzata L, Liao Y, et al
    Mismatch Repair Polymorphisms as Markers of Breast Cancer Prevalence in the Breast Cancer Family Registry.
    Anticancer Res. 2016;36:4437-41.
    PubMed     Text format     Abstract available


  189. DO SI, Yoon G, Kim HS, Kim K, et al
    Increased Brahma-related Gene 1 Expression Predicts Distant Metastasis and Shorter Survival in Patients with Invasive Ductal Carcinoma of the Breast.
    Anticancer Res. 2016;36:4873-82.
    PubMed     Text format     Abstract available


    August 2016

  190. Handbook of HER2-Targeted Agents in Breast Cancer.
    Anticancer Res. 2016;36:4377.
    PubMed     Text format    


  191. KARLIKOVA M, Topolcan O, Narsanska A, Kucera R, et al
    Circulating Growth and Angiogenic Factors and Lymph Node Status in Early-stage Breast Cancer - A Pilot Study.
    Anticancer Res. 2016;36:4209-14.
    PubMed     Text format     Abstract available


  192. PIMENTEL C, Becquet M, Lavoue V, Henno S, et al
    Ovarian Metastases from Breast Cancer: A Series of 28 Cases.
    Anticancer Res. 2016;36:4195-200.
    PubMed     Text format     Abstract available


  193. KAPPIL MA, Liao Y, Terry MB, Santella RM, et al
    DNA Repair Gene Expression Levels as Indicators of Breast Cancer in the Breast Cancer Family Registry.
    Anticancer Res. 2016;36:4039-44.
    PubMed     Text format     Abstract available


  194. CHIANG KC, Hsu SY, Lin SJ, Yeh CN, et al
    PTEN Insufficiency Increases Breast Cancer Cell Metastasis In Vitro and In Vivo in a Xenograft Zebrafish Model.
    Anticancer Res. 2016;36:3997-4005.
    PubMed     Text format     Abstract available


  195. FULAWKA L, Halon A
    Proliferation Index Evaluation in Breast Cancer Using ImageJ and ImmunoRatio Applications.
    Anticancer Res. 2016;36:3965-72.
    PubMed     Text format     Abstract available


  196. HOWARD CB, McDowell R, Feleke K, Deer E, et al
    Chemotherapeutic Vulnerability of Triple-negative Breast Cancer Cell-derived Tumors to Pretreatment with Vernonia amygdalina Aqueous Extracts.
    Anticancer Res. 2016;36:3933-43.
    PubMed     Text format     Abstract available


  197. BENDRAT K, Fritz P, Muller S, Brockmoller S, et al
    Improved Risk Stratification for Breast Cancer Samples Based on the Expression Ratio of the Estrogen and Progesterone Receptor.
    Anticancer Res. 2016;36:3855-63.
    PubMed     Text format     Abstract available


  198. YANO S, Takehara K, Miwa S, Kishimoto H, et al
    In Vivo Isolation of a Highly-aggressive Variant of Triple-negative Human Breast Cancer MDA-MB-231 Using Serial Orthotopic Transplantation.
    Anticancer Res. 2016;36:3817-20.
    PubMed     Text format     Abstract available



  199. Breast Disease. Management and Therapies.
    Anticancer Res. 2016;36:4376.
    PubMed     Text format    


  200. LUCZYNSKA E, Heinze S, Adamczyk A, Rys J, et al
    Comparison of the Mammography, Contrast-Enhanced Spectral Mammography and Ultrasonography in a Group of 116 patients.
    Anticancer Res. 2016;36:4359-66.
    PubMed     Text format     Abstract available


  201. FUJII T, Yajima R, Kuwano H
    Implications of Long-term Indwelling of Tissue Expander in Breast Reconstruction: Risk of Expander Rupturing.
    Anticancer Res. 2016;36:4337-40.
    PubMed     Text format     Abstract available


    July 2016
  202. NAM SO, Yotsumoto F, Miyata K, Fukagawa S, et al
    Anti-tumor Effect of Intravenous Administration of CRM197 for Triple-negative Breast Cancer Therapy.
    Anticancer Res. 2016;36:3651-7.
    PubMed     Text format     Abstract available


  203. SHIMAMURA Y, Tamatani D, Kuniyasu S, Mizuki Y, et al
    5-Aminolevulinic Acid Enhances Ultrasound-mediated Antitumor Activity via Mitochondrial Oxidative Damage in Breast Cancer.
    Anticancer Res. 2016;36:3607-12.
    PubMed     Text format     Abstract available


  204. CRISCITIELLO C, Bagnardi V, Viale G, Disalvatore D, et al
    HER2 Equivocal Status in Early Breast Cancer Is Not Associated with Higher Risk of Recurrence.
    Anticancer Res. 2016;36:3537-40.
    PubMed     Text format     Abstract available


  205. SU CH, Lane HY, Hsiao CL, Liu LC, et al
    Matrix Metalloproteinase-1 Genetic Polymorphism in Breast Cancer in Taiwanese.
    Anticancer Res. 2016;36:3341-3345.
    PubMed     Text format     Abstract available


  206. SAMARA P, Skopeliti M, Tsiatas ML, Georgaki S, et al
    A Cytokine Cocktail Augments the Efficacy of Adoptive NK-92 Cell Therapy Against Mouse Xenografts of Human Cancer.
    Anticancer Res. 2016;36:3373-82.
    PubMed     Text format     Abstract available


    June 2016

  207. Novel Biomarkers in the Continuum of Breast Cancer.
    Anticancer Res. 2016;36:3224.
    PubMed     Text format    


  208. ANDERGASSEN U, Vogl A, Mumm JN, Kolbl AC, et al
    Immunocytochemical Characterization of Disseminated Tumour Cells from Bone Marrow of Breast Cancer Patients.
    Anticancer Res. 2016;36:3217-22.
    PubMed     Text format     Abstract available


  209. KOLBL AC, Brauer D, Hutter S, Rack B, et al
    New Marker Genes for Real-Time PCR-based Detection of Circulating Tumour Cells from Blood of Breast Cancer Patients.
    Anticancer Res. 2016;36:3211-6.
    PubMed     Text format     Abstract available


  210. KOLBEN T, Hary T, Holdt LM, Schwarz TM, et al
    Thyroid Hormones and Vitamin D in Patients with Breast Cancer with Mutations in BRCA1 or BRCA2 Genes.
    Anticancer Res. 2016;36:3185-90.
    PubMed     Text format     Abstract available


  211. FREIER CP, Kuhn C, Endres S, Mayr D, et al
    FOXP3+ Cells Recruited by CCL22 into Breast Cancer Correlates with Less Tumor Nodal Infiltration.
    Anticancer Res. 2016;36:3139-45.
    PubMed     Text format     Abstract available


  212. KONIG A, Vilsmaier T, Rack B, Friese K, et al
    Determination of Interleukin-4, -5, -6, -8 and -13 in Serum of Patients with Breast Cancer Before Treatment and its Correlation to Circulating Tumor Cells.
    Anticancer Res. 2016;36:3123-30.
    PubMed     Text format     Abstract available


  213. FUJII T, Yajima R, Tsuboi M, Higuchi T, et al
    Clinicopathological Features of Cases with Primary Breast Cancer not Identified by 18F-FDG-PET.
    Anticancer Res. 2016;36:3019-22.
    PubMed     Text format     Abstract available


  214. SHIMA H, Kutomi G, Satomi F, Maeda H, et al
    SOX2 and ALDH1 as Predictors of Operable Breast Cancer.
    Anticancer Res. 2016;36:2945-53.
    PubMed     Text format     Abstract available


  215. BRAUTIGAM K, Mitzlaff K, Uebel L, Koster F, et al
    Subtypes of Triple-negative Breast Cancer Cell Lines React Differently to Eribulin Mesylate.
    Anticancer Res. 2016;36:2759-66.
    PubMed     Text format     Abstract available


  216. SCHELZ Z, Ocsovszki I, Bozsity N, Hohmann J, et al
    Antiproliferative Effects of Various Furanoacridones Isolated from Ruta graveolens on Human Breast Cancer Cell Lines.
    Anticancer Res. 2016;36:2751-8.
    PubMed     Text format     Abstract available


  217. KASSAYOVA M, Bobrov N, Strojny L, Orendas P, et al
    Anticancer and Immunomodulatory Effects of Lactobacillus plantarum LS/07, Inulin and Melatonin in NMU-induced Rat Model of Breast Cancer.
    Anticancer Res. 2016;36:2719-28.
    PubMed     Text format     Abstract available


  218. KIM JY, Heo SH, Song IH, Park IA, et al
    Activation of the PERK-eIF2alpha Pathway Is Associated with Tumor-infiltrating Lymphocytes in HER2-Positive Breast Cancer.
    Anticancer Res. 2016;36:2705-11.
    PubMed     Text format     Abstract available


  219. MIN DJ, He S, Green JE
    Birinapant (TL32711) Improves Responses to GEM/AZD7762 Combination Therapy in Triple-negative Breast Cancer Cell Lines.
    Anticancer Res. 2016;36:2649-57.
    PubMed     Text format     Abstract available


    April 2016
  220. WINDRICHOVA J, Fuchsova R, Kucera R, Topolcan O, et al
    Testing of a Novel Cancer Metastatic Multiplex Panel for the Detection of Bone-metastatic Disease - a Pilot Study.
    Anticancer Res. 2016;36:1973-8.
    PubMed     Text format     Abstract available


  221. RAPOSO TP, Beirao BC, Pires I, Prada J, et al
    Immunohistochemical Expression of CCR2, CSF1R and MMP9 in Canine Inflammatory Mammary Carcinomas.
    Anticancer Res. 2016;36:1805-13.
    PubMed     Text format     Abstract available


  222. MOSS T, Chirico A, Mallia L, Lucidi F, et al
    Psychosocial Outcomes of Quadrantectomy Versus Mastectomy in a Southern Italian Sample: Development and Needs of the Italian Derriford Appearance Scale 24.
    Anticancer Res. 2016;36:1519-26.
    PubMed     Text format     Abstract available


    March 2016
  223. CUI YX, Evans BA, Jiang WG
    New Roles of Osteocytes in Proliferation, Migration and Invasion of Breast and Prostate Cancer Cells.
    Anticancer Res. 2016;36:1193-201.
    PubMed     Text format     Abstract available


    February 2016
  224. AMABILE MI, Monti M, Merola R, Frusone F, et al
    Nipple-sparing Mastectomy in Patients with Preoperative Diagnosis of Non-invasive Breast Carcinoma. A Single-center Experience.
    Anticancer Res. 2016;36:779-83.
    PubMed     Text format     Abstract available


  225. KUCERA R, Topolcan O, Fiala O, Kinkorova J, et al
    The Role of TPS and TPA in the Diagnostics of Distant Metastases.
    Anticancer Res. 2016;36:773-7.
    PubMed     Text format     Abstract available


    January 2016
  226. GITT A, Bose-Ribeiro H, Nieder C, Kup PG, et al
    Treatment Results of MammoSite Catheter in Combination with Whole-breast Irradiation.
    Anticancer Res. 2016;36:355-60.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: